DGAP-News: Ergomed plc gibt Platzierungsergebnis bekannt

Ergomed plc gibt Platzierungsergebnis bekannt

^

DGAP-News: Ergomed plc / Schlagwort(e): Kapitalerhöhung

Ergomed plc gibt Platzierungsergebnis bekannt

28.09.2017 / 12:48

Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

---------------------------------------------------------------------------

DIESE PRESSEMITTEILUNG UND DIE DARIN ENTHALTENEN INFORMATIONEN DIENEN NICHT

DER DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG, IM GANZEN

ODER IN AUSZÜGEN, IN DEN ODER IN DIE VEREINIGTEN STAATEN VON AMERIKA,

AUSTRALIEN, KANADA, JAPAN, REPUBLIK VON IRLAND ODER REPUBLIK VON SÜDAFRIKA

ODER EINE ANDERE JURISDIKTION, IN DER EIN SOLCHES VORGEHEN UNGESETZMÄSSIG

WÄRE

Ergomed plc gibt Platzierungsergebnis bekannt

London, UK - 28. September 2017: Ergomed plc ("Ergomed" oder "das

Unternehmen"; AIM: ERGO LN, Xetra: 2EM GR), ein auf pharmazeutische

Dienstleistungen und Arzneimittelentwicklung spezialisiertes Unternehmen,

freut sich das Ergebnis einer heute angekündigten Platzierung (die

"Platzierung") bekannt zu geben.

Insgesamt wurden 1.757.576 neue Stammaktien des Unternehmens im Nennwert von

je 1 Pence pro Aktie (die "Platzierungsaktien") zu einem Preis von 165 Pence

pro Aktie (der "Platzierungspreis") platziert, wodurch ein

Bruttoemissionserlös von GBP 2,9 Mio. (vor Aufwendungen) erzielt wird, der

die Akquisition der PSR Group BV in Teilen finanziert.

Die auszugebenden Platzierungsaktien entsprechen etwa 4,3% des bestehenden

Grundkapitals des Unternehmens. Der Platzierungspreis entspricht einem

Abschlag von etwa 4,1% auf den volumengewichteten Durchschnittskurs der

Aktien des Unternehmens während der letzten 30 Handelstage.

Die Platzierung wurde von Numis Securities Limited ("Numis") und N+1 Singer

Advisory LLP ("N+1 Singer") als Joint Bookrunners durchgeführt. Soweit nicht

anders definiert gilt für die in dieser Mitteilung verwendeten

hervorgehobenen Begriffe die Bedeutung, welche ihnen in der der Mitteilung,

die das Unternehmen heute Morgen um 7.00 Uhr BST veröffentlicht hat,

zugewiesen wurde.

Beteiligungen von Organmitgliedern (Directors)

Die Beteiligung von Organmitgliedern von Ergomed, die Platzierungsaktien zum

Platzierungspreis aufgenommen haben, gestaltet sich wie folgt:

Di- Beteili- Aggregierter Anzahl Beteiligung Daraus

rec- gung in Wert der zu der zu in resultierende

tor Stammak- erwerbenden erwerben- Stammaktien Beteiligung an

tien Stammaktien den nach der Stammaktien an dem

(£) Stammakti- Platzierung erhöhten

en Grundkapitals in %

Pe- 231.250 74.250,00 45.000 276.250 0,65%

ter

Ge-

or-

ge

Zulassung

Für die Platzierungsaktien ist der Antrag auf Zulassung zum Handel an der

Londoner Börse (AIM) ("Zulassung") bereits gestellt worden. Derzeit wird

erwartet, dass die Abwicklung und die Zulassung aller Platzierungsaktien am

oder um den 2. Oktober 2017 herum um 8.00 Uhr BST stattfinden wird. Die

Platzierung hängt unter anderem von dem Wirksamwerden der Zulassung ab und

davon, ob die Platzierungsvereinbarung unwiderruflich wird und nicht gemäß

ihrer Konditionen für nichtig erklärt wird.

Gesamtstimmrechte

Nach der Zulassung wird sich die neue Gesamtzahl der Stammaktien im Nennwert

von je 1 Pence pro Aktie am Grundkapital der Gesellschaft und die Zahl der

Stimmrechte auf 42.680.813 belaufen. Der obige Wert kann von den Aktionären

als Richtwert in der Berechnung genutzt werden, mithilfe der sie bestimmen

können, inwiefern sie unter Berücksichtigung der Offenlegungs- und

Transparenzbestimmungen der Finanzaufsichtsbehörden dazu verpflichtet sind,

ihre Beteiligung oder die Veränderung ihrer Beteiligung an dem Unternehmen

mitzuteilen.

Nachstehend die veröffentlichte Pressemitteilung in voller Länge.

Anmerkung: Bitte beachten Sie, dass die einzig offizielle Pressemitteilung

die vom Unternehmen in englischer Sprache veröffentlichte Meldung ist. Die

obige Zusammenfassung und Übersetzung dient lediglich der vereinfachten

Informationsbereitstellung.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR

PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN

PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE

REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER

JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Ergomed plc

Result of Placing

London, UK - 28 September 2017: Ergomed plc (AIM: ERGO) ("Ergomed" or the

"Company"), a specialised pharmaceutical services and drug development

company, is pleased to announce the result of the placing announced earlier

today (the "Placing").

A total of 1,757,576 new ordinary shares in the Company of 1p each (the

"Placing Shares") have been conditionally placed at a price of 165p per

Placing Share (the "Placing Price"), raising proceeds of £2.9m (before

expenses) to part-fund the acquisition of PSR Group BV.

The Placing Shares to be issued represent approximately 4.3% of the

Company's existing issued ordinary share capital. The Placing Price

represents a discount of approximately 4.1% to the Company's last 30 trading

days volume weighted average price.

Numis Securities Limited ("Numis") and N+1 Singer Advisory LLP ("N+1

Singer") have acted as joint bookrunners in respect of the Placing. Other

than where defined, capitalised terms used in this announcement have the

meanings given to them in the announcement released by the Company this

morning at 7.00 a.m.

Director participation

The participation of Directors of Ergomed who have taken up Placing Shares

at the Placing Price is as follows:

Di- Inte- Aggregate Number of Interest in Resulting holding

rec- rest in value of Ordinary Ordinary of Ordinary

tor Ordina- Ordinary Shares to Shares Shares as % of

ry Shares to be be following enlarged issued

Shares acquired (£) acquired the Placing share capital

Pe- 231,250 74,250.00 45,000 276,250 0.65%

ter

Ge-

or-

ge

Admission

Application has been made to the London Stock Exchange for the Placing

Shares to be admitted to trading on AIM ("Admission"). It is currently

expected that settlement of all of the Placing Shares and Admission will

take place at 8.00 a.m. on or around 2 October 2017. The Placing is

conditional upon, inter alia, Admission becoming effective and the Placing

Agreement becoming unconditional and not being terminated in accordance with

its terms.

Total voting rights

Following Admission the number of ordinary shares of 1 penny each in the

capital of the Company in issue and number of voting rights will be

42,680,813. The above figure may be used by Shareholders as the denominator

for the calculations by which they will determine whether they are required

to notify their interest in, or a change to their interest in, the Company

under the Financial Conduct Authority's Disclosure and Transparency Rules.

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial

responsibilities/person closely associated

a) Name Peter

George

2 Reason for the notification

a) Position/status Chairman

b) Initial notification /Amendment Initial

Notificati-

on

3 Details of the issuer, emission allowance

market participant, auction platform,

auctioneer or auction monitor

a) Name Ergomed Plc

b) Legal Entity Identifier 213800BVS8I-

9VMC1AP84

4 Details of the transaction(s): section to be

repeated for (i) each type of instrument;

(ii) each type of transaction; (iii) each

date; and (iv) each place where transactions

have been conducted

a) Description of the financial instrument, Ordinary

type of instrument Identification code shares of 1

pence each

GB00BN7ZCY6-

7

b) Nature of the transaction Purchase of

shares

c) Currency GBP

d) Price(s) and volume(s) Price(s) Volume(s)

16- 45,000

5p

e) Aggregated information - Aggregated volume - 45,000 165p

Price - Aggregated total £74,250.00

f) Date of the transaction 28

September

2017

g) Place of the transaction London

Stock

Exchange,

AIM

Enquiries:

Ergomed plc Tel: +44 (0) 1483

503205

Dan Weng (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)

Numis Securities Limited Tel: +44 (0) 20

7260 1000

Michael Meade / Freddie Barnfield (Nominated

Adviser)

James Black (Joint Broker)

N+1 Singer Tel: +44 (0) 20

7496 3000

Alex Price (Joint Broker) Michael Taylor

Consilium Strategic Communications - for UK Tel: +44 (0) 20

enquiries 3709 5700

Chris Gardner / Mary-Jane Elliott Ivar Milligan ergomed@consilium-

/ Philippa Gardner comms.com

MC Services - for Continental European enquiries Tel: +49 211 5292

5222

Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and

develops drugs both wholly-owned and through partnerships. Ergomed's

fast-growing, profitable service offering spans all phases of clinical

development and post-approval pharmacovigilance and medical information.

Drawing on more than 20 years of expertise in drug development, Ergomed is

also building a growing portfolio of drug development partnerships and

programmes, including wholly-owned proprietary products for the treatment of

surgical bleeding. For further information, visit: http://ergomedplc.com

About PSR

PSR, established in 1998, is a full service specialist orphan drug CRO and

recognised as a leading expert in the rare disease niche. PSR specialises in

running complex orphan drug development programs requiring innovative

regulatory and clinical approaches as well as pricing and reimbursement

strategies. Besides outsourced project solutions, PSR provides insourced

staffing solutions (orphan drug teams), temporary & permanent staffing,

interim management solutions as well as training / coaching career programs.

PSR's dedication to the rare disease landscape is exemplified by an

extensive track record of orphan drug projects in a wide range of

therapeutic areas, its continued efforts to achieve true patient centricity

and its societal commitments by participation in fundraising activities and

public-private partnerships. For further information, visit:

http://www.psr-group.com.

This announcement contains inside information which is disclosed in

accordance with the Market Abuse Regulation.

Each of Numis Securities Limited and Nplus1 Singer Advisory LLP, both of

which are regulated in the UK by the Financial Conduct Authority, is acting

for the Company and no one else in connection with the Placing, and will not

be responsible to any person other than the Company for providing the

regulatory and legal protections afforded to their respective clients nor

for providing advice in relation to the contents of this Announcement or any

matter, transaction or arrangement referred to in it.

This Announcement includes statements, estimates, opinions and projections

with respect to anticipated future performance of the Company or future

events ("forward-looking statements") which reflect various assumptions

concerning anticipated results or events which may or may not prove to be

correct. These forward looking statements can be identified by the use of

forward looking terminology, including the terms "anticipates", "target",

"believes", "estimates", "expects", "intends", "may", "plans", "projects",

"should" or "will", or, in each case, their negative or other variations or

comparable terminology or by discussions of strategy, plans, objectives,

goals, future events or intentions. Such forward-looking statements reflect

current expectations based on the current business plan and various other

assumptions and involve significant risks and uncertainties and should not

be read as guarantees of future performance or results and will not

necessarily be accurate indications of whether or not such results will be

achieved. As a result, prospective investors should not rely on such

forward-looking statements due to the inherent uncertainty therein. No

representation or warranty is given as to the completeness or accuracy of

the forward-looking statements contained in this Announcement.

Forward-looking statements speak only as of the date of such statements and,

except as required by the FCA, the London Stock Exchange or applicable law,

the Company undertakes no obligation to update or revise publicly any

forward-looking statements, whether as a result of new information, future

events or otherwise. No statement in this Announcement is intended to be a

profit forecast and no statement in this Announcement should be interpreted

to mean that earnings per share of the Company for the current or future

financial years would necessarily match or exceed the historical published

earnings per share of the Company. The price of shares and the income from

them may go down as well as up and investors may not get back the full

amount invested on disposal of the Placing Shares.

The distribution of this Announcement and the offering of the Placing Shares

in certain jurisdictions may be restricted by law. No action has been taken

by the Company or the Bookrunners that would permit an offering of the

Placing Shares or possession or distribution of this Announcement or any

other offering or publicity material relating to the Placing Shares in any

jurisdiction where action for that purpose is required. Persons into whose

possession this Announcement comes are required by the Company and the

Bookrunners to inform themselves about, and to observe, such restrictions.

The Placing Shares to be issued pursuant to the Placing will not be admitted

to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by

hyperlinks on the Company's website is incorporated in, or forms part of,

this Announcement.

---------------------------------------------------------------------------

28.09.2017 Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch DGAP - ein Service der EQS Group AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,

Corporate News/Finanznachrichten und Pressemitteilungen.

Medienarchiv unter http://www.dgap.de

---------------------------------------------------------------------------

613957 28.09.2017

°